Radiotherapy in England in 2007: Modelled Demand and Audited Activity

Clinical Oncology

Volumn 21, Issue 8, 2009, Pages 575-590

  Williams, M V ^a   Drinkwater, K J ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF RADIOLOGISTS   (United Kingdom)

Author keywords

Access; capacity; demand; fractionation; modelling; radiotherapy

Indexed keywords

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; COLON CANCER; ESOPHAGUS CANCER; EVIDENCE BASED PRACTICE; HEAD AND NECK CANCER; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; INTERNET; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL AUDIT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MELANOMA; NATIONAL HEALTH SERVICE; OVARY CANCER; PANCREAS CANCER; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RECTUM CANCER; SARCOMA; SKIN CANCER; STOMACH CANCER; THEORY; TREATMENT DURATION; TREATMENT PLANNING; UNITED KINGDOM; UTERUS CANCER;

DOSE FRACTIONATION; ENGLAND; FEMALE; HUMANS; MALE; MEDICAL AUDIT; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE;

EID: 69649093855     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.07.003     Document Type: Article

References (60)

1. Williams M.V., Summers E.T., Drinkwater K.J., and Barrett A. Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005. Clin Oncol 19 (2007) 273-286
2. Tyldesley S., Boyd C., Sulze K., Walker H., and MacKillop W.J. Estimating the need for radiotherapy for lung cancer: an evidence-based epidemic approach. Int J Radiat Oncol Biol Phys 49 (2001) 973-985
3. Delaney G.P., Jacob S., Featherstone C., and Barton N.B. Radiotherapy in cancer care; estimating optimal utilisation from a review of evidence-based clinical guidelines (2003), Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital, Sydney Australia. http://www.canceraustralia.gov.au/media/3425/radiotherapyreport.pdf 2003. [accessed 19.01.09]
4. Delaney G.P., Jacob S., Featherstone C., and Barton N.B. The role of radiotherapy in cancer treatment: estimating optimal utilisation from a review of evidence-based clinical guidelines. Cancer 104 (2005) 1129-1137
5. The Scottish Government. Cancer in Scotland: radiotherapy activity planning 2011-15 (2005), Scottish Executive, Edinburgh. http://www.scotland.gov.uk/Publications/2006/01/24131719/0 Available from:
6. Erridge S.C., Featherstone C., Chalmers R., Campbell J., Stockton D., and Black R. What will be the radiotherapy machine capacity required for optima delivery of radiotherapy in Scotland in 2015?. Eur J Cancer 43 (2007) 1802-1809
7. Bentzen S.M., Herren G., Cottier B., et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: ESTRO QUARTS Project. Radiother Oncol 75 (2005) 355-365
8. Moller H., Fairley L., Coupland V., et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer 96 (2007) 1484-1488
9. Department of Health. Radiotherapy: developing a world class service for England, 2007. Available from:. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publicati onsPolicyAndGuidance/DH_074575 [accessed 19.01.09]
10. Department of Health. Scenario subgroup - predicting future demand for radiotherapy, 2007. Available from:. http://www.cancer.nhs.uk/documents/nrag_files/scenario%20sub%20group%20r eport%20-%20jan%2007%20-%20fin.pdf [accessed 19.01.09]
11. Moller T.R., Brorrson B., Ceberg J., et al. A prospective survey of radiotherapy practice in 2001 in Sweden. Acta Oncol 42 (2003) 387-410
12. Drinkwater K.J., and Williams M. Re-audit of radiotherapy waiting times in the United Kingdom, 2007. Available from:. http://www.rcr.ac.uk/docs/general/pdf/ReportUKFINAL100408.pdf 2008. [accessed 19.01.09]
13. Summers E., and Williams M. Re-audit of radiotherapy waiting times 2005. Available from:. www.rcr.ac.uk/docs/general/pdf/RTWT2005report.pdf [accessed 19.01.09]
14. Department of Health. Advice to NRAG. Appendix A: treatment trees by cancer site, 2007. Available from:. http://www.cancer.nhs.uk/documents/nrag_files/scenario%20%20report%20app endix%20a%20-%20treatment%20trees%20-%20fin.pdf 2007. [accessed 19.01.09]
15. Department of Health. Cancer Reform Strategy (2007), Department of Health, London. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publicati onsPolicyAndGuidance/DH_081006 Available from:
16. Welsh Assembly Government. Radiotherapy equipment needs and workforce implications 2006-2016. Cancer Services Co-ordinating Group Radiotherapy and Chemotherapy Advisory Group. Available from: (2006). http://new.wales.gov.uk/about/departments/dhss/publications/health_pub_i ndex/reports/radiotherapyequipmentneeds?lang=en [accessed 19.01.09]
17. National Cancer Services Analysis Team (Natcansat). UK national radiotherapy equipment survey, 2007. Available from:. http://www.canceruk.net/rtservices/rtequip2007 2008. [accessed 19.01.09]
18. Oliver R.T., Mason M.D., Mead G.M., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366 (2005) 293-330
19. The Royal College of Radiologists. Radiotherapy dose-fractionation (2006), The Royal College of Radiologists, London. Available from: http://www.rcr.ac.uk/publications.aspx?PageID=149&PublicationID=229
20. The START Trialists' Group. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypo-fractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9 (2008) 331-341
21. The START Trialists' Group. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypo-fractionation for treatment of early breast cancer: a randomised trial. Lancet 371 (2008) 1098-1107
22. Hiley C., Tutt A., Torres M., and Palmieri C. Adjuvant radiotherapy for breast cancer. Br Med J 337 (2008) a2843
23. The Information Centre. National head and neck cancer audit. DAHNO third annual report (2008), The Health and Social Care Information Centre, London. http://www.ic.nhs.uk/services/national-clinical-audit-support-programme- ncasp/audit-reports/head-and-neck-cancer Available from:
24. Gowda R.V., Henk J., Mais K.L., et al. Three weeks' radiotherapy for T1 glotic cancer: the Christie and Royal Marsden Hospital experience. Radiother Oncol 68 (2003) 105-111
25. National Institute for Clinical Excellence. The diagnosis and treatment of lung cancer (2005), National Collaborating Centre for Acute Care at The Royal of Surgeons of England, London. http://www.nice.org.uk/guidance/CG24 Available from:
26. Rowell N.P., and O'Rourke N.P. Synchronous chemoradiotherapy in non-small cell lung cancer. (Cochrane review in progress). Cochrane Database Syst Rev (2004) Issue 1:CDO02140
27. Williams M.V., James N.D., Summers E.T., Barrett A., and Ash D.V. National survey of radiotherapy fractionation practice in 2003. Clin Oncol 18 (2006) 3-14
28. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev (2000) Issue 2:CDO02139
29. The Information Centre. National lung cancer audit, 2006 (2007), The Information Centre, Leeds. http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/1910 0507%20IC%20Lung%20Cancer%20Audit%20Report%202006-FV.pdf Available from
30. Imperatori A., Harrison R.N., Leitch D.N., et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 61 (2006) 232-239
31. Khoo V.S., and Dearnaley D.P. Question of dose-fractionation and technique: ingredients for testing hypo fractionation in prostate cancer - the CHHiP trial. Clin Oncol 20 (2008) 12-14
32. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment (2008), National Institute for Health and Clinical Excellence, London. http://www.nice.org.uk/Guidance/CG58 Available from:
33. Hoskin P.J. Hypo fractionation in prostate cancer: how far can we go?. Clin Oncol 20 (2008) 727-728
34. Tang C.I., Loblaw D.A., Cheung P., et al. Phase I/II study of 5-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART 3. Clin Oncol 20 (2008) 729-737
35. Hawkins M.A., and Tait V. Locally advanced non-metastatic cancer - can we do more?. Clin Oncol 20 (2008) 532-534
36. National Cancer Institute. Pancreatic cancer treatment. Available from:. http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofes sional [accessed 19.01.09]
37. Sultana A., Tudur Smith C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 (2007) 1183-1190
38. Gastrointestinal Tumour Study Group. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic cancer. Int J Radiat Oncol Biol Phys 9 (1979) 5
39. Gastrointestinal Tumour Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
40. Burris III H.A., Moore M.J., Anderson J., et al. Improvements in survival and clinical benefit for gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomised trial. J Clin Oncol 15 (1997) 2403-2413
41. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Eng J Med 350 (2004) 1200-1210
42. Koshy M.C., Landry J.C., Cavanaugh S.X., et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 61 (2005) 965-966
43. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299 (2008) 1019-1026 [Erratum 2008;299:1902]
44. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (2008) 1592-1599
45. NCRI Upper GI Clinical Studies Group. Selective chemo radiation in advanced localised pancreatic cancer. SCALOP trial. Available from: (2008). http://ncrndev.org.uk/index.php?option=com_content&task=view&id= 135&Itemid=273
46. Sebag-Montefiore D., Stephens R.J., Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG CO16): a randomised clinical trial. Lancet 373 (2009) 811-820
47. Quirke P., Steele R., Monson J., et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373 (2009) 821-828
48. Madoff R.D. Rectal cancer: optimum treatment leads to optimum results. (Editorial). Lancet 373 (2009) 790-791
49. Craven I., and Sebag-Montefiore D. Is there a role for radiotherapy in operable rectal cancer?. Clin Oncol 19 (2007) 687-692
50. Glynne-Jones R. UK third national colorectal cancer consensus meeting 2008. (Editorial). Clin Oncol 21 (2009) 306-310
51. Kerba M., Miao Q., Zhang-Salomons J., and Mackillop W. Defining the need to breast cancer radiotherapy in the general population: the criterion based bench marking approach. Clin Oncol 19 (2007) 481-489
52. Punglia R.S., Weeks J.C., Neville B.A., and Earle C.C. Effective distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women. Int J Radiat Oncol Biol Phys 66 (2006) 56-63
53. Voti L., Richardson L.C., Reis I.M., Fleming L.E., Mackinon J., and Coebergh J.W. Treatment of local breast carcinoma in Florida: the role of distance to radiation treatment therapy facilities. Cancer 106 (2006) 201-207
54. Jones A.P., Haynes R., Sauerzapf V., Crawford S.M., Zhao H., and Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary, prostate cancer. Eur J Cancer 44 (2008) 992-999
55. The Royal College of Radiologists. Guidance on the development and management of devolved radiotherapy services (2004), The Royal College of Radiologists, London. https://www.rcr.ac.uk/docs/oncology/pdf/Management_Devolved_ Radiotherapy_Services.pdf Available from:
56. National Cancer Services Analysis Team (Natcansat). Downloads: NRAG interactive toolkit, 2009. Available from:. http://www.canceruk.net/downloads/nrag/ 2009. [accessed 19.01.09]
57. Williams M.V., and Drinkwater K.J. Geographical variation in radiotherapy services across the UK in 2007 and the impact of deprivation. Clin Oncol 21 (2009) 431-440
58. Royal College of Radiologists, Society and College of Radiographers, Institute of Physics and Engineering in Medicine, National Patient Safety Agency, and British Institute of Radiology. Towards safer radiotherapy (2008), The Royal College of Radiologists, London. https://www.rcr.ac.uk/docs/oncology/pdf/Towards_saferRT_final.pdf Available from:
59. The Royal College of Radiologists, The Society and the College of Radiographers, The Royal College of Nursing, and the Institute of Physics and Engineering in Medicine. Breaking the mould: roles, responsibilities and skills mix in departments of clinical oncology (2002), The Royal College of Radiologists, London. Available from: https://rcr.ac.uk/publications.aspx?PageID=149&PublicationID=180
60. College of Radiographers. A strategy for the education and professional development of radiographers (2002), College of Radiographers, London